FDA enforcement has reached a new corner of the grey-market GLP-1 trade: overseas websites selling unapproved injectable semaglutide under brand names tied to major Indian drugmakers. Two warning letters, issued a day apart, order the sellers to stop.
What Happened
The U.S. FDA sent warning letters to two online sellers for marketing unapproved injectable semaglutide directly to American consumers. A September 24, 2026 letter to Cheap Medicine Shop targeted a product listed as Semanext Injection; a September 23 letter to Online Generic Medicine targeted Semanat Injection. The agency confirmed neither product is approved for U.S. sale and that no marketing application was ever filed for either.
The listings were sold without requiring a prescription. FDA-approved semaglutide products carry a boxed warning about thyroid C-cell tumors; the unapproved copies carried inadequate labeling, making them misbranded under the FD&C Act.
Who Is Affected
U.S. buyers hunting for cut-price weight-loss injections are the direct audience — and the direct risk. The Semanext brand name has real-world provenance: it belongs to a semaglutide product launched in India by Zydus under a co-marketing agreement with Lupin announced in March 2026. The FDA named neither company, and neither firm has an FDA-approved semaglutide product for the U.S. market. The letters target the unauthorized sellers, not the manufacturers — but a familiar brand name on a vial is not proof of a legitimate supply chain.
Timeline
- March 2026 — Indian drugmakers announce their semaglutide licensing and co-marketing partnership for the Indian market
- September 23, 2026 — FDA warning letter to Online Generic Medicine over "Semanat Injection"
- September 24, 2026 — FDA warning letter to Cheap Medicine Shop over "Semanext Injection"
- October 2026 — The flagged listing is removed from the seller's website; the FDA describes the risk to prior buyers as material
What This Means for Researchers
- Unapproved is not generic. India's generic semaglutide industry is expanding, but U.S. patents and FDA approval requirements still block lawful entry. No FDA-approved generic semaglutide exists in the United States.
- Brand-name borrowing complicates attribution. Grey-market sellers adopting established brand names make it harder to trace where a vial was actually made.
- Injectables raise the stakes. FDA notes unapproved injectable products bypass the body's natural defenses; contamination can lead to life-threatening sepsis.
- Enforcement is watching the import channel. As demand for cheaper GLP-1s grows, warning letters are the first step toward import alerts and seizures.
How to Verify Your Peptides
- Buy semaglutide only from a licensed U.S. pharmacy with a valid prescription — no legitimate FDA-approved product ships from an overseas retail website
- Treat any "generic Ozempic" or "generic Wegovy" claim as false; none is FDA-approved
- If you already purchased from an overseas seller, independent lab testing can check identity and purity — see our semaglutide testing and COA verification guide
Safe Alternatives
- Read our semaglutide research profile for what approved products actually contain and how they are regulated
- Compare sources in our vetted vendor directory
- Ask a licensed clinician about FDA-approved GLP-1 options dispensed through regulated pharmacies
Sources
U.S. FDA warning letters dated September 23 and 24, 2026; regulatory announcements; industry reports.